🏛️ Verified NIH Record • Updated 2025-10-13
LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) (NCT05321420)
A Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: PureTech
🩺 Plain-English Summary (8th-Grade Level)
This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults with Idiopathic Pulmonary Fibrosis.
Who can join: Review the eligibility criteria below.
Location: University of Alabama Birmingham — Birmingham, Alabama
Age range: 40 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (103 Sites)
Showing the first 25 of 103 sites.
- University of Alabama Birmingham — Birmingham, Alabama
- Science 37 — Los Angeles, California
- NewportNativeMD, Inc. — Newport Beach, California
- Paradigm Clinical Research Centers, Inc. — Redding, California
- Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center — Torrance, California
- University of Connecticut Health Center — Farmington, Connecticut
- Accel Research Sites Network — DeLand, Florida
- Harmony Medical Research Institute, Inc — Hialeah, Florida
- Piedmont Healthcare, Inc. — Atlanta, Georgia
- Clinical Research Investments — Decatur, Georgia
- Indiana University School of Medicine — Indianapolis, Indiana
- University of Kansas Medical Center — Kansas City, Kansas
- Pulmonix — Greensboro, North Carolina
- Southeastern Research Center — Winston-Salem, North Carolina
- University of Cincinnati — Cincinnati, Ohio
- Temple University — Philadelphia, Pennsylvania
- Clinical Trials Center of Middle Tennessee — Franklin, Tennessee
- Vanderbilt University Medical Center — Nashville, Tennessee
- Baylor Scott & White Research Institute — Dallas, Texas
- Renovatio Clinical - The Woodlands Research Center — The Woodlands, Texas
- Pulmonary Associates of Richmond — Richmond, Virginia
- TPMG Clinical Research — Williamsburg, Virginia
- Instituto Médico de la Fundación de Estudios Clinicos / Fundación Estudios — Rosario, Santa Fe Province
- Aprillus Asistencia e Investigación — Buenos Aires,
- CEMER Centro Medico de Enfermedades Respiratorias — Buenos Aires,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Idiopathic Pulmonary Fibrosis
- Atezolizumab for Idiopathic Pulmonary Fibrosis — Los Angeles, California
- A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) — Quilmes, Buenos Aires
- A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis — Birmingham, Alabama
- Yoga Effect on Quality of Life Study Among Patients with Idiopathic Pulmonary Fibrosis — Seattle, Washington
- MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) — Camperdown, New South Wales
Explore by condition: All Idiopathic Pulmonary Fibrosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.